KLRK1 and neoplasm: Following the design of such an NKAB-ErbB2 molecule carrying the tumor-targeting domain at the N-terminus and the NKG2D-specific domain at the C-terminus, here, we generated a similar NKAB-EGFR antibody for the redirection of effector lymphocytes to tumor cells overexpressing epidermal growth factor receptor (EGFR) (Figure 4A).